Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Regulation of mitochondrial oxidative metabolism by tumor suppressor FLCN.

Hasumi H, Baba M, Hasumi Y, Huang Y, Oh H, Hughes RM, Klein ME, Takikita S, Nagashima K, Schmidt LS, Linehan WM.

J Natl Cancer Inst. 2012 Nov 21;104(22):1750-64. doi: 10.1093/jnci/djs418. Epub 2012 Nov 12.

2.

Birt-Hogg-Dubé syndrome: Clinical and molecular aspects of recently identified kidney cancer syndrome.

Hasumi H, Baba M, Hasumi Y, Furuya M, Yao M.

Int J Urol. 2016 Mar;23(3):204-10. doi: 10.1111/iju.13015. Epub 2015 Nov 25. Review.

3.

The tumor suppressor folliculin regulates AMPK-dependent metabolic transformation.

Yan M, Gingras MC, Dunlop EA, Nouët Y, Dupuy F, Jalali Z, Possik E, Coull BJ, Kharitidi D, Dydensborg AB, Faubert B, Kamps M, Sabourin S, Preston RS, Davies DM, Roughead T, Chotard L, van Steensel MA, Jones R, Tee AR, Pause A.

J Clin Invest. 2014 Jun;124(6):2640-50. doi: 10.1172/JCI71749. Epub 2014 Apr 24.

4.

Birt-Hogg-Dubé syndrome: from gene discovery to molecularly targeted therapies.

Schmidt LS.

Fam Cancer. 2013 Sep;12(3):357-64. doi: 10.1007/s10689-012-9574-y. Erratum in: Fam Cancer. 2013 Sep;12(3):365.

5.

Folliculin-interacting proteins Fnip1 and Fnip2 play critical roles in kidney tumor suppression in cooperation with Flcn.

Hasumi H, Baba M, Hasumi Y, Lang M, Huang Y, Oh HF, Matsuo M, Merino MJ, Yao M, Ito Y, Furuya M, Iribe Y, Kodama T, Southon E, Tessarollo L, Nagashima K, Haines DC, Linehan WM, Schmidt LS.

Proc Natl Acad Sci U S A. 2015 Mar 31;112(13):E1624-31. doi: 10.1073/pnas.1419502112. Epub 2015 Mar 16.

6.

Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys.

Baba M, Furihata M, Hong SB, Tessarollo L, Haines DC, Southon E, Patel V, Igarashi P, Alvord WG, Leighty R, Yao M, Bernardo M, Ileva L, Choyke P, Warren MB, Zbar B, Linehan WM, Schmidt LS.

J Natl Cancer Inst. 2008 Jan 16;100(2):140-54. doi: 10.1093/jnci/djm288. Epub 2008 Jan 8.

7.

Birt-Hogg-Dubé renal tumors are genetically distinct from other renal neoplasias and are associated with up-regulation of mitochondrial gene expression.

Klomp JA, Petillo D, Niemi NM, Dykema KJ, Chen J, Yang XJ, Sääf A, Zickert P, Aly M, Bergerheim U, Nordenskjöld M, Gad S, Giraud S, Denoux Y, Yonneau L, Méjean A, Vasiliu V, Richard S, MacKeigan JP, Teh BT, Furge KA.

BMC Med Genomics. 2010 Dec 16;3:59. doi: 10.1186/1755-8794-3-59.

8.

Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia.

Chen J, Futami K, Petillo D, Peng J, Wang P, Knol J, Li Y, Khoo SK, Huang D, Qian CN, Zhao P, Dykema K, Zhang R, Cao B, Yang XJ, Furge K, Williams BO, Teh BT.

PLoS One. 2008;3(10):e3581. doi: 10.1371/journal.pone.0003581. Epub 2008 Oct 30. Erratum in: PLoS ONE. 2008;3(11). doi: 10.1371/annotation/0f06471c-1993-4144-b785-d58924ac0b5c. PLoS ONE. 2008;3(11). doi: 10.1371/annotation/136385d5-b241-4ecc-b31a-6dea3ebf3bc4. Dykyma, Karl [corrected to Dykema, Karl].

9.

Tumor suppressor FLCN inhibits tumorigenesis of a FLCN-null renal cancer cell line and regulates expression of key molecules in TGF-beta signaling.

Hong SB, Oh H, Valera VA, Stull J, Ngo DT, Baba M, Merino MJ, Linehan WM, Schmidt LS.

Mol Cancer. 2010 Jun 23;9:160. doi: 10.1186/1476-4598-9-160.

10.

Interaction of folliculin (Birt-Hogg-Dubé gene product) with a novel Fnip1-like (FnipL/Fnip2) protein.

Takagi Y, Kobayashi T, Shiono M, Wang L, Piao X, Sun G, Zhang D, Abe M, Hagiwara Y, Takahashi K, Hino O.

Oncogene. 2008 Sep 11;27(40):5339-47. doi: 10.1038/onc.2008.261. Epub 2008 Jul 28.

PMID:
18663353
11.

Establishment and characterization of BHD-F59RSVT, an immortalized cell line derived from a renal cell carcinoma in a patient with Birt-Hogg-Dubé syndrome.

Furuya M, Hasumi H, Baba M, Tanaka R, Iribe Y, Onishi T, Nagashima Y, Nakatani Y, Isono Y, Yao M.

Lab Invest. 2017 Mar;97(3):343-351. doi: 10.1038/labinvest.2016.137. Epub 2016 Dec 19.

12.

Renal tumour suppressor function of the Birt-Hogg-Dubé syndrome gene product folliculin.

Hudon V, Sabourin S, Dydensborg AB, Kottis V, Ghazi A, Paquet M, Crosby K, Pomerleau V, Uetani N, Pause A.

J Med Genet. 2010 Mar;47(3):182-9. doi: 10.1136/jmg.2009.072009. Epub 2009 Oct 19.

PMID:
19843504
13.

Birt-Hogg-Dubé: tumour suppressor function and signalling dynamics central to folliculin.

Tee AR, Pause A.

Fam Cancer. 2013 Sep;12(3):367-72. doi: 10.1007/s10689-012-9576-9.

PMID:
23096221
14.

H255Y and K508R missense mutations in tumour suppressor folliculin (FLCN) promote kidney cell proliferation.

Hasumi H, Hasumi Y, Baba M, Nishi H, Furuya M, Vocke CD, Lang M, Irie N, Esumi C, Merino MJ, Kawahara T, Isono Y, Makiyama K, Warner AC, Haines DC, Wei MH, Zbar B, Hagenau H, Feigenbaum L, Kondo K, Nakaigawa N, Yao M, Metwalli AR, Marston Linehan W, Schmidt LS.

Hum Mol Genet. 2017 Jan 15;26(2):354-366. doi: 10.1093/hmg/ddw392.

15.

Nutrient-induced FNIP degradation by SCFβ-TRCP regulates FLCN complex localization and promotes renal cancer progression.

Nagashima K, Fukushima H, Shimizu K, Yamada A, Hidaka M, Hasumi H, Ikebe T, Fukumoto S, Okabe K, Inuzuka H.

Oncotarget. 2017 Feb 7;8(6):9947-9960. doi: 10.18632/oncotarget.14221.

16.

Birt-Hogg-Dube syndrome is a novel ciliopathy.

Luijten MN, Basten SG, Claessens T, Vernooij M, Scott CL, Janssen R, Easton JA, Kamps MA, Vreeburg M, Broers JL, van Geel M, Menko FH, Harbottle RP, Nookala RK, Tee AR, Land SC, Giles RH, Coull BJ, van Steensel MA.

Hum Mol Genet. 2013 Nov 1;22(21):4383-97. doi: 10.1093/hmg/ddt288. Epub 2013 Jun 19.

17.

Knockdown of Slingshot 2 (SSH2) serine phosphatase induces Caspase3 activation in human carcinoma cell lines with the loss of the Birt-Hogg-Dubé tumour suppressor gene (FLCN).

Lu X, Boora U, Seabra L, Rabai EM, Fenton J, Reiman A, Nagy Z, Maher ER.

Oncogene. 2014 Feb 20;33(8):956-65. doi: 10.1038/onc.2013.27. Epub 2013 Feb 18.

PMID:
23416984
18.

Therapeutic targeting the loss of the birt-hogg-dube suppressor gene.

Lu X, Wei W, Fenton J, Nahorski MS, Rabai E, Reiman A, Seabra L, Nagy Z, Latif F, Maher ER.

Mol Cancer Ther. 2011 Jan;10(1):80-9. doi: 10.1158/1535-7163.MCT-10-0628.

19.

Absence of the Birt-Hogg-Dubé gene product is associated with increased hypoxia-inducible factor transcriptional activity and a loss of metabolic flexibility.

Preston RS, Philp A, Claessens T, Gijezen L, Dydensborg AB, Dunlop EA, Harper KT, Brinkhuizen T, Menko FH, Davies DM, Land SC, Pause A, Baar K, van Steensel MA, Tee AR.

Oncogene. 2011 Mar 10;30(10):1159-73. doi: 10.1038/onc.2010.497. Epub 2010 Nov 8.

20.

FLCN: The causative gene for Birt-Hogg-Dubé syndrome.

Schmidt LS, Linehan WM.

Gene. 2018 Jan 15;640:28-42. doi: 10.1016/j.gene.2017.09.044. Epub 2017 Sep 29. Review.

PMID:
28970150

Supplemental Content

Support Center